[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB1026401A - Isatin thiosemicarbazones,their preparation and pharmaceutical formulations containing them - Google Patents

Isatin thiosemicarbazones,their preparation and pharmaceutical formulations containing them

Info

Publication number
GB1026401A
GB1026401A GB666461A GB666461A GB1026401A GB 1026401 A GB1026401 A GB 1026401A GB 666461 A GB666461 A GB 666461A GB 666461 A GB666461 A GB 666461A GB 1026401 A GB1026401 A GB 1026401A
Authority
GB
United Kingdom
Prior art keywords
group
preparation
alkyl
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB666461A
Inventor
Denis John Bauer
Peter William Sadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Priority to GB666461A priority Critical patent/GB1026401A/en
Publication of GB1026401A publication Critical patent/GB1026401A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention comprises compounds of the general formula <FORM:1026401/C2/1> (wherein R1 is a hydrogen atom or an alkyl, hydroxyalkyl or alkenyl group containing up to 5 carbon atoms and the hydroxy group may itself be esterified by a C1- 5 aliphatic carboxylic acid radical, R2 is an optional substituent and if present is a halogen atom or a C1- 5 alkyl or alkoxy group, and R5 and R6 are the same or different and are straight or branched alkyl or alkenyl groups containing up to 5 carbon atoms each or -NR5R6 is a saturated or unsaturated heterocyclic group containing no further hetero atom, a morpholino group or a piperazino group wherein the second nitrogen atom may be substituted by a C1- 5 alkyl group) and acid addition salts of those compounds which are basic, pharmaceutical preparations containing them, and their preparation by reacting a compound of the formula <FORM:1026401/C2/2> with a compound of the formula H2N.NH.CS.NR5R6 optionally followed by acid addition salt formation when the product is basic. The preparation of a number of starting materials of the third general formula above and salts thereof, in most cases from the corresponding thiocarbamoylthioglycollic acids (preparation described), and of acetophenone 4,4 - (3 - methyl - 3 - azapentamethylene)thiosemicarbazone is described. The compounds of the invention have anti-viral activity and may be administered in the form of pharmaceutical preparations (e.g. tablets, capsules, cachets, ampoules, suppositories, powders, granules, solutions, suspensions and ointments) containing them together with a carrier.
GB666461A 1961-02-23 1961-02-23 Isatin thiosemicarbazones,their preparation and pharmaceutical formulations containing them Expired GB1026401A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB666461A GB1026401A (en) 1961-02-23 1961-02-23 Isatin thiosemicarbazones,their preparation and pharmaceutical formulations containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB666461A GB1026401A (en) 1961-02-23 1961-02-23 Isatin thiosemicarbazones,their preparation and pharmaceutical formulations containing them

Publications (1)

Publication Number Publication Date
GB1026401A true GB1026401A (en) 1966-04-20

Family

ID=9818567

Family Applications (1)

Application Number Title Priority Date Filing Date
GB666461A Expired GB1026401A (en) 1961-02-23 1961-02-23 Isatin thiosemicarbazones,their preparation and pharmaceutical formulations containing them

Country Status (1)

Country Link
GB (1) GB1026401A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2184944A (en) * 1986-01-01 1987-07-08 Univ Ramot Antiviral agents
WO1998030660A1 (en) * 1997-01-10 1998-07-16 Uniroyal Chemical Company, Inc. Dithiocarbamyl carboxylic acids and their use as multifunctional additives for lubricating oils
WO2008083491A1 (en) * 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
WO2010006438A1 (en) * 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2184944A (en) * 1986-01-01 1987-07-08 Univ Ramot Antiviral agents
GB2184944B (en) * 1986-01-01 1989-12-28 Univ Ramot Antiviral agents
WO1998030660A1 (en) * 1997-01-10 1998-07-16 Uniroyal Chemical Company, Inc. Dithiocarbamyl carboxylic acids and their use as multifunctional additives for lubricating oils
US8822475B2 (en) 2007-01-11 2014-09-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
WO2008083491A1 (en) * 2007-01-11 2008-07-17 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
JP2010515693A (en) * 2007-01-11 2010-05-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド Compounds and methods for the treatment of cancer
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8367675B2 (en) 2007-01-11 2013-02-05 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8420643B2 (en) 2007-01-11 2013-04-16 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8580792B2 (en) 2007-01-11 2013-11-12 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
WO2010006438A1 (en) * 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9422282B2 (en) 2010-04-01 2016-08-23 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9624220B2 (en) 2010-04-01 2017-04-18 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV

Similar Documents

Publication Publication Date Title
GB1398426A (en) Heterocyclic substituted guanidines
GB1026401A (en) Isatin thiosemicarbazones,their preparation and pharmaceutical formulations containing them
GB1456627A (en) Pyridobenzodiazepinones
GB1296544A (en)
GB1016071A (en) New guanidine derivatives and process for preparing the same
IE36127L (en) 3-benzylpyridines
GB1137764A (en) Improvements in or relating to pharmacologically-active secondary amines
DE2965701D1 (en) 1-imidazol-2-ylidene-3-thienyl-urea derivatives, processes therefor, and pharmaceutical compositions
GB984471A (en) Anthranilic acid esters and methods for producing the same
GB1307256A (en) Piperazine derivatives and a process for their preparation
GB1353508A (en) Aminoisoquinolines
GB1449802A (en) Piperazine derivatives and compositions containing them for treating parkinsons disease
GB868552A (en) Improvements in or relating to novel amidines and the preparation thereof
GB1254270A (en) Benzoxazepine derivatives
GB1369888A (en) Substituted amidines
GB1021522A (en) 2-quinolone derivatives
GB1318859A (en) Imidazo-4,5-b-pyridine derivatives
GB981533A (en) Derivatives of phenylalanine
GB877106A (en) Substituted urea complex salts
ES359070A1 (en) 6-(4-alkylpiperazin-1-yl)phenanthridines
GB1032377A (en) Asymmetrical pyridoxolyl disulphides and their preparation
GB1298507A (en) N-substituted 3-carbamoyl-1-thia-isochroman-1,1-dioxide derivatives
ES337592A1 (en) Novel acrylic acid derivatives and process for the preparation thereof
GB1308832A (en) Pyridazine derivatives
GB1005728A (en) New amino-guanidines and process for their manufacture